Next-Gen Modality Convergence: ADCs, Radiopharmaceuticals, Bispecifics, and Protein Degraders

Session details:

The strongest pipelines in 2026 are being built around new ways to reach previously 'undruggable' targets, deliver payloads more precisely, and more effectively leverage known targets using novel technologies for improved efficacy and safety. This panel maps where the field is converging and what it means for development strategy, patient impact and the future therapeutic landscape in oncology and beyond. 

Key discussion points: 
• Opportunities for Nex-Gen modalities 
• Pipeline considerations: Prioritization, resource allocation, risk and cost
• Development challenges: Preclinical development, manufacturing, clinical execution
• Future landscape: Impact on patients and treatment paradigms